In MS patients, activated platelets can produce IL-1α, triggering endothelial activation and the release of sCD40L and PF4/CXCL4, leading to altered BBB permeability (Wachowicz et al., 2016). This evidence concerns the gene PF4 and myeloid sarcoma.